- Q3 2026 net sales: EUR14,444 million, +14.3% CER
- Q3 2026 business EPS: EUR3.55, +19.6% CER
Sanofi reported Q3 net sales of EUR14.4 billion, up 14.3% at constant exchange rates, and business EPS of EUR3.55, up 19.6% at CER. Dupixent sales rose 34.8% to EUR5.7 billion. The company upgraded its full-year guidance to low-teens sales growth and mid-teens business EPS growth at CER.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.